Highlights
- 1Clinical and translational medicine · 2025
- 2Advances in experimental medicine and biology · 2022
- 3Cell reports. Medicine · 2025
Publications
64 publications
Funding
6 grantsView NIH portfolio on RePORTER ↗
Active
4 grants- PITargeting Cullin-RING E3 ubiquitin ligase 1 to treat ovarian cancerMary Kay Foundation, The · 2025–2027MKF 10-25
- Co-IClinical and Translational Science Center- Institutional CTSC Internal Funding UL1CTSC Cost Share · 2022–2027UL1TR002384-06
- PIAmgen Contract No. 5209583Amgen Inc. · 2025–2026BioPharma AllianceBP 262629-01
- Co-IDiversifying Patient-Derived Tumor OrganoidsParker Institute for Cancer Immunotherapy · 2024–2026PICI IC-594
Completed grants (2)
- PIUtilizing Precision Medicine to elucidate the mechanisms underpinning treatment efficacyNCI · 2019–2022 · via NIH RePORTERR00CA230384-04
- PIUtilizing Precision Medicine to elucidate the mechanisms underpinning treatment efficacyNational Cancer Institute · 2018–2019K99CA230384-01
News mentions
1 mentionView all WCM news ↗
- New Precision Medicine Approach Identifies a Promising Ovarian Cancer TreatmentJuly 7, 2025
A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators.
External relationships
Ownership
FAETH Therapeutics
Proprietary Interest
FAETH Therapeutics
Other
FAETH Therapeutics